A PHASE 3, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF MICAFUNGIN (FK463) VERSUS CASPOFUNGIN AS ANTIFUNGAL TREATMENT IN PATIENTS WITH INVASIVE CANDIDIASIS OR CANDIDEMIA
Latest Information Update: 03 Aug 2021
At a glance
- Drugs Micafungin (Primary) ; Caspofungin
- Indications Candidaemia; Invasive candidiasis
- Focus Therapeutic Use
- Sponsors Astellas Pharma US
- 06 Sep 2019 New trial record